The 'Covishield' vaccine's trials begin with the first patients screened by Bharati Vidyapeeth Deemed University (BVDU) Medical College and Hospital in Pune
The hospital aims to have about 300-350 participants as part of the trial
The Oxford covid vaccine is seen one of the leading vaccine candidates
New Delhi: Serum Institute of India’s trial for ‘Covishield’ vaccine developed by the University of Oxford started on Tuesday, with the first patients screened by Bharati Vidyapeeth Deemed University (BVDU) Medical College and Hospital in Pune.
“Today, we have screened some patients. Tomorrow, we will get their covid antibody test reports, and if they come negative, we will inoculate with the ‘Covishield’ vaccine," Sanjay Lalwani, principal investigator for the hospital told Mint, adding that the hospital aims to have about 300-350 participants as part of the trial.
Indian Council of Medical Research director general Balram Bhargava on Tuesday confirmed that the trials for the ‘Covishield’ vaccine, jointly developed by the University of Oxford and Astrazeneca plc, have begun. ICMR is the secondary sponsor to the phase 2 and 3 trial of around 1,600 patients.
Screening and enrolment of participants in the trial is only done after getting approval from the ethics committee of the hospital. So far, seven hospitals, including BVDU, of the 17 sites have received ethics committee approval, according to the government’s clinical trial registry.
Other hospitals that received ethics committee approval, which include Jehangir Clinical Development Center and KEM Hospital in Pune, King George Hospital at Visakhapatnam, Rajendra Memorial Research Institute of Medical Sciences at Patna, are expected to start screening of patients later this week. About two or three days after the approval, the hospitals will start giving doses of the vaccine, a source in the know said, requesting anonymity.
Serum Institute, which is the world’s largest vaccine manufacturer by volume, had in June signed an agreement with British-Swedish multinational pharmaceutical company AstraZeneca to supply an additional 1 billion doses, principally for low- and middle-income countries.
As it is a contract manufacturer of the vaccine, the company had secured the Indian drug regulator’s approval to conduct a phase II and III trial as per regulations.
Pune-based Serum Institute is the third firm to conduct human trials of a covid-19 vaccine in India after Bharat Biotech (for Covaxin) and Zydus Cadila (for ZyCoV-D) started phase I and II trails last month.
Interim data from a clinical study published in The Lancet journal last month showed that the Oxford vaccine candidate was safe and provided dual immunity against the highly infectious respiratory disease.
The Bill & Melinda Gates Foundation will provide at-risk funding of $150 million to support Serum Institute of India’s manufacturing of two promising vaccines by University of Oxford and Novavax under the condition that the Pune-based firm prices the two vaccines at a maximum of $3 per dose.
Source - livemint
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.